TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer

TRIP13促进易出错的非同源末端连接,并诱导头颈癌的化疗耐药性。

阅读:3
作者:Rajat Banerjee,Nickole Russo,Min Liu,Venkatesha Basrur,Emily Bellile,Nallasivam Palanisamy,Christina S Scanlon,Elizabeth van Tubergen,Ronald C Inglehart,Tarek Metwally,Ram-Shankar Mani,Anastasia Yocum,Mukesh K Nyati,Rogerio M Castilho,Sooryanarayana Varambally,Arul M Chinnaiyan,Nisha J D'Silva

Abstract

Squamous cell carcinoma of the head and neck (SCCHN) is a common, aggressive, treatment-resistant cancer with a high recurrence rate and mortality, but the mechanism of treatment resistance remains unclear. Here we describe a mechanism where the AAA-ATPase TRIP13 promotes treatment resistance. Overexpression of TRIP13 in non-malignant cells results in malignant transformation. High expression of TRIP13 in SCCHN leads to aggressive, treatment-resistant tumors and enhanced repair of DNA damage. Using mass spectrometry, we identify DNA-PKcs complex proteins that mediate nonhomologous end joining (NHEJ), as TRIP13-binding partners. Using repair-deficient reporter systems, we show that TRIP13 promotes NHEJ, even when homologous recombination is intact. Importantly, overexpression of TRIP13 sensitizes SCCHN to an inhibitor of DNA-PKcs. Thus, this study defines a new mechanism of treatment resistance in SCCHN and underscores the importance of targeting NHEJ to overcome treatment failure in SCCHN and potentially in other cancers that overexpress TRIP13.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。